The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Fibroblast Growth Factor 21 Corrects Obesity in Mice
Abstract
Fibroblast growth factor 21 (FGF21) is a metabolic regulator that provides efficient and durable glycemic and lipid control in various animal models. However, its potential to treat obesity, a major health concern affecting over 30% of the population, has not been fully explored. Here we report that systemic administration of FGF21 for 2 wk in diet-induced obese and ob/ob mice lowered their mean body weight by 20% predominantly via a reduction in adiposity. Although no decrease in total caloric intake or effect on physical activity was observed, FGF21-treated animals exhibited increased energy expenditure, fat utilization, and lipid excretion, reduced hepatosteatosis, and ameliorated glycemia. Transcriptional and blood cytokine profiling studies revealed effects consistent with the ability of FGF21 to ameliorate insulin and leptin resistance, enhance fat oxidation and suppress de novo lipogenesis in liver as well as to activate futile cycling in adipose. Overall, these data suggest that FGF21 exhibits the therapeutic characteristics necessary for an effective treatment of obesity and fatty liver disease and provides novel insights into the metabolic determinants of these activities.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“prolonged administration of FGF21 or FGF21 analogues has important metabolic effects, including a marked decrease in body weight in rodents and non-human primates, and more modest effects on body weight in humans3,40,58,77,78.”
From Metabolic messengers: FGF21 (2021) · cites this paper as [77]
In the citing paper
“Pharmacological administration of FGF21 to obese rodents reverses diabetes and obesity through increasing energy expenditure77,78.”
From Metabolic messengers: FGF21 (2021) · cites this paper as [77]
In the citing paper
“Pharmacological administration of FGF21 decreases plasma glucose and lipid levels, improves insulin and leptin sensitivity, decreases hepatic steatosis, increases energy expenditure [[131], [132], [133], [134], [135], [136]], and decreases sugar and alcohol intake in mice [[137], [138], [139], [140], [141], [142]].”
From Hepatokines and metabolism: Deciphering communication from the liver (2021) · cites this paper as [131]
In the citing paper
“Pharmacological administration of FGF21 decreases plasma glucose and lipid levels, improves insulin and leptin sensitivity, decreases hepatic steatosis, increases energy expenditure [[131], [132], [133], [134], [135], [136]], and decreases sugar and alcohol intake in mice [[137], [138], [139], [140], [141], [142]].”
From Hepatokines and metabolism: Deciphering communication from the liver (2021) · cites this paper as [131]
In the citing paper
“Pharmacological administration of FGF21 decreases plasma glucose and lipid levels, improves insulin and leptin sensitivity, decreases hepatic steatosis, increases energy expenditure [[131], [132], [133], [134], [135], [136]], and decreases sugar and alcohol intake in mice [[137], [138], [139], [140], [141], [142]].”
From Hepatokines and metabolism: Deciphering communication from the liver (2021) · cites this paper as [131]
In the citing paper
“Pharmacological administration of FGF21 decreases plasma glucose and lipid levels, improves insulin and leptin sensitivity, decreases hepatic steatosis, increases energy expenditure [[131], [132], [133], [134], [135], [136]], and decreases sugar and alcohol intake in mice [[137], [138], [139], [140], [141], [142]].”
From Hepatokines and metabolism: Deciphering communication from the liver (2021) · cites this paper as [131]
In the citing paper
“A myriad of studies ensued demonstrating that administering FGF21 to obese or diabetic rodents and primates markedly reduced body weight and significantly improved carbohydrate and lipid homeostasis (21, 64, 65, 141).”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [21]
In the citing paper
“When administered to diabetic and obese animal models, FGF21 provides multiple metabolic benefits and has been shown to decrease blood glucose levels and body weight, improve insulin and leptin sensitivity, improve plasma lipid profiles, and decrease hepatic steatosis (21, 64, 141, 142).”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [21]
In the citing paper
“Importantly, in animal models FGF21 treatment not only prevents (64) but also reverses diabetes and obesity (21, 141).”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [21]
In the citing paper
“Since FGF21 administration increases energy expenditure and the browning of adipose tissues in vivo (21, 64, 141), it was hypothesized that FGF21 regulates adaptive thermogenesis in response to cold.”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [21]
In the citing paper
“It is clear that FGF21 treatment elicits significant metabolic changes in many tissues, including the liver and adipose tissues (21, 141).”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [21]
In the citing paper
“FGF21’s ability to reduce body weight, glucose levels, and lipid concentrations in models of obesity generated substantial initial interest”
From FGF21 and the physiological regulation of macronutrient preference (2020) · cites this paper as [116]
Citations
Cites
Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation
Watanabe, M., Houten, S. M., Mataki, C., Christoffolete, M. A., Kim, B. W., Sato, H., Messaddeq, N., Harney, J. W., Ezaki, O., Kodama, T., et al. (2006) · Nature · doi:10.1038/nature04330 · Cited by 2,220
FGF-21 as a novel metabolic regulator
Kharitonenkov, A., Shiyanova, T. L., Koester, A., Ford, A. M., Micanovic, R., Galbreath, E. J., Sandusky, G. E., Hammond, L. J., Moyers, J. S., Owens, R. A., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23606 · Cited by 2,125
Self-citationCellular signaling by fibroblast growth factor receptors
Eswarakumar, V. P., Lax, I., & Schlessinger, J. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.01.001 · Cited by 1,923
Inagaki, T., Dutchak, P., Zhao, G., Ding, X., Gautron, L., Parameswara, V., Li, Y., Goetz, R., Mohammadi, M., Esser, V., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.003 · Cited by 1,504
Badman, M. K., Pissios, P., Kennedy, A. R., Koukos, G., Flier, J. S., & Maratos-Flier, E. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.002 · Cited by 1,495
Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young
Fajans, S. S., Bell, G. I., & Polonsky, K. S. (2001) · New England Journal of Medicine · doi:10.1056/nejmra002168 · Cited by 1,123
Handschin, C., & Spiegelman, B. M. (2006) · Endocrine Reviews · doi:10.1210/er.2006-0037 · Cited by 1,090
New drug targets for type 2 diabetes and the metabolic syndrome
Moller, D. E. (2001) · Nature · doi:10.1038/414821a · Cited by 1,012
Self-citationIdentification of a novel FGF, FGF-21, preferentially expressed in the liver
Nishimura, T., Nakatake, Y., Konishi, M., & Itoh, N. (2000) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(00)00067-1 · Cited by 847
Role for Stearoyl-CoA Desaturase-1 in Leptin-Mediated Weight Loss
Cohen, P., Miyazaki, M., Socci, N. D., Hagge-Greenberg, A., Liedtke, W., Soukas, A. A., Sharma, R., Hudgins, L. C., Ntambi, J. M., & Friedman, J. M. (2002) · Science · doi:10.1126/science.1071527 · Cited by 826
Flagged first, then by citations
Cited by
Sorted by citations
Items 801–900 of 995
FGF21 Normalizes Plasma Glucose in Mouse Models of Type 1 Diabetes and Insulin Receptor Dysfunction
Diener, J. L., Mowbray, S. F., Huang, W.-J., Yowe, D. L., Xu, J., Caplan, S. L., Misra, A., Kapur, A., Shapiro, J., Ke, X., et al. (2021) · Endocrinology · doi:10.1210/endocr/bqab092 · Cited by 9
Nakagawa, Y., Kumagai, K., Han, S., Mizunoe, Y., Araki, M., Mizuno, S., Ohno, H., Matsuo, K., Yamada, Y., Kim, J., et al. (2021) · The FASEB Journal · doi:10.1096/fj.202002784rr · Cited by 11
The Diagnostic Role of FGF 21 in Endometrial Cancer and Other Pathologies of the Uterine Corpus
Jagodzińska, A., Chudecka-Glaz, A. M., Michalczyk, K., Pius‐Sadowska, E., Wieder-Huszla, S., Jurczak, A., & Machaliński, B. (2023) · Diagnostics · doi:10.3390/diagnostics13030399 · Cited by 9
Kakoty, V., Sarathlal, K. C., Yang, C., Dubey, S. K., & Taliyan, R. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00659 · Cited by 9
Biology of Stress Responses in Aging
Calubag, M. F., Ademi, I., Yeh, C., Babygirija, R., Bhoopat, A. M., Kasza, I., Sonsalla, M. M., Green, C. L., Pak, H. H., & Lamming, D. W. (2023) · doi:10.59368/agingbio.20230002 · Cited by 10
Fibroblast growth factor 21 decreases after liver fat reduction via growth hormone augmentation
Braun, L. R., Feldpausch, M. N., Czerwonka, N., Torriani, M., Grinspoon, S. K., & Stanley, T. L. (2017) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2017.10.002 · Cited by 9
Yen, H., Hsieh, S., Chen, C., Yang, W., Lee, P., Lin, M., Chen, C., & Yang, P. (2020) · Scientific Reports · doi:10.1038/s41598-020-62395-z · Cited by 9
Tang, S., & Borlak, J. T. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70218 · Cited by 8
Fibroblast Growth Factor 21 Is Elevated in HIV and Associated With Interleukin-6
Eckard, A. R., Hughes, H., Hagood, N. L., O’Riordan, M. A., Labbato, D. E., Kosco, J. C., Scott, S., & McComsey, G. A. (2020) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002285 · Cited by 8
Optimization of Peptide Inhibitors of β-Klotho as Antagonists of Fibroblast Growth Factors 19 and 21
Pan, J. B., Parlee, S. D., Brunel, F. M., Li, P., Lu, W., Pérez–Tilve, D., Liu, F., Finan, B., Kharitonenkov, A., & DiMarchi, R. D. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00100 · Cited by 9
Self-citationChen, W., Shen, Z., Cai, S., Chen, L., & Wang, D. (2021) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/133494 · Cited by 8
Impact of sex on the adaptation of adult mice to long consumption of sweet-fat diet
Бажан, Н. М., Iakovleva, T., Dubinina, A., & En, M. (2020) · Vavilov Journal of Genetics and Breeding · doi:10.18699/vj20.682 · Cited by 8
Sostre‐Colón, J., Gavin, M. J., Santoleri, D., & Titchenell, P. M. (2022) · Endocrinology · doi:10.1210/endocr/bqac035 · Cited by 7
Guerra, N. P., Leyens, K., Müller, L., Brauer, D., Janowitz, D., Schlick, S., Pilz, K., Grabe, H. J., Vollmar, B., & Kuhla, A. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.935805 · Cited by 8
Бажан, Н. М., Jakovleva, T., Kazantseva, A. Y., Костина, Н. Е., Orlov, P. E., Balybina, N., Baranov, K. O., & En, M. (2023) · Vavilov Journal of Genetics and Breeding · doi:10.18699/vjgb-23-40 · Cited by 9
Boparai, R. K., Arum, O., Miquet, J. G., Masternak, M. M., Bartke, A., & Khardori, R. K. (2015) · International Journal of Endocrinology · doi:10.1155/2015/282375 · Cited by 8
Kikai, M., Yamada, H., Wakana, N., Terada, K., Yamamoto, K., Wada, N., Motoyama, S., Saburi, M., Sugimoto, T., Irie, D., et al. (2017) · Cardiovascular Research · doi:10.1093/cvr/cvx212 · Cited by 9
RetractedFernandes, M. J., Hechtman, P., Boulay, B., & Kaplan, F. (1997) · European Journal of Human Genetics · doi:10.1159/000484748 · Cited by 8
Kalkan, K. K., Şen, S., Narlı, B., Seymen, C. M., & Yılmaz, C. (2023) · Molecular Biology Reports · doi:10.1007/s11033-023-08444-y · Cited by 7
Functions of FGF21 and its role in cardiac hypertrophy
Chen, L., Gao, M., Ong, S., & Gong, G. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.03.007 · Cited by 7
Zhang, H., Xiong, P., Zheng, T., Hu, Y., Guo, P., Shen, T., & Zhou, X. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094170 · Cited by 7
Generation of bispecific antibodies by structure-guided redesign of IgG constant regions
Iwasaki, Y. W., Tharakaraman, K., Subramanian, V., Khongmanee, A., Hatas, A., Fleischer, E., Rurak, T. T., Ngok-ngam, P., Tit-oon, P., Ruchirawat, M., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1063002 · Cited by 7
Patterns of Circulating Fibroblast Growth Factor 21 in Subjects with and without Type 2 Diabetes
Lu, J., Yu, H., Mo, Y., Ma, X., Hao, Y., Lu, W., Li, H., Bao, Y., Zhou, J., & Jia, W. (2015) · PLoS ONE · doi:10.1371/journal.pone.0142207 · Cited by 7
He, Y., Li, Y., Wei, Z., Zhang, X., Gao, J., Wang, X., Li, X., Wu, W., Li, W., Yi, X., et al. (2018) · Drug Testing and Analysis · doi:10.1002/dta.2365 · Cited by 7
Roles of FGF21 and irisin in obesity-related diabetes and pancreatic diseases
Xie, T., & Leung, P. S. (2020) · Journal of Pancreatology · doi:10.1097/jp9.0000000000000039 · Cited by 7
Fibroblast growth factor 21: a novel long-acting hypoglycemic drug for canine diabetes
Jiang, X., Liu, S., Wang, Y., Zhang, R., Opoku, Y. K., Xie, Y.-Z., Li, D., & Ren, G. (2020) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-020-02023-9 · Cited by 7
Girer, N. G., Rontoyanni, V. G., Joshi, A., Patrikeev, I., Murton, A. J., Porter, C. C., Motamedi, M., & Elferink, C. J. (2021) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.121.000514 · Cited by 7
Qin, B., Qincao, L., He, S., Liao, Y., Shi, J., Xie, F., Diao, N., & Bai, L. (2021) · Endocrine Journal · doi:10.1507/endocrj.ej20-0728 · Cited by 7
Estradiol-dependent and independent effects of FGF21 in obese female mice
Jakovleva, T. V., Kazantseva, A. Y., Dubinina, A. D., Balybina, N. Y., Baranov, K. O., Makarova, E. N., & Бажан, Н. М. (2022) · Vavilov Journal of Genetics and Breeding · doi:10.18699/vjgb-22-20 · Cited by 7
Chiu, L.-T., Wang, C., Lin, Y., & Hsu, B. (2022) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2022.05.007 · Cited by 7
Research Progress of Fibroblast Growth Factor 21 in Fibrotic Diseases
Jia, M.-Q., Guan, C., Tao, J., & Zhou, Y. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/5042762 · Cited by 7
Fibroblast growth factor 21 ameliorates cholestatic liver injury via a hepatic FGFR4-JNK pathway
Zhou, C., Pan, X., Huang, L., Wu, T., Zhao, T., Qi, J., Wu, J., Mukondiwa, A. V., Tang, Y., Luo, Y., et al. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166870 · Cited by 7
Pálsdóttir, V., Windahl, S. H., Hägg, D. A., Keantar, H., Bellman, J., Buchanan, A. G., Vaughan, T. J., Lindén, D., Jansson, J., & Ohlsson, C. (2019) · Endocrinology · doi:10.1210/en.2018-01002 · Cited by 8
Guerra, N. P., Parveen, A., Bühler, D., Brauer, D., Müller, L., Pilz, K., Witt, M., Glass, A. S., Bajorat, R., Janowitz, D., et al. (2021) · Nutrients · doi:10.3390/nu13092916 · Cited by 8
Sleeve gastrectomy attenuates high fat diet-induced non-alcoholic fatty liver disease
Pei, E., Liu, Y., Jiang, W., Lin, S., Huang, L., Lin, M., & Cai, L. (2018) · Lipids in Health and Disease · doi:10.1186/s12944-018-0875-5 · Cited by 7
Delgado‐Anglés, A., Blasco‐Roset, A., Godoy-Nieto, F. J., Cairó, M., Villarroya, F., Giralt, M., & Villarroya, J. (2023) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-023-00977-x · Cited by 7
Sexual dimorphism of MASLD-driven bone loss
Goldscheitter, G., Seneshaw, M., Mirshahi, F., Buettmann, E. G., Genetos, D. C., Sanyal, A. J., & Donahue, H. J. (2025) · Scientific Reports · doi:10.1038/s41598-025-08693-w · Cited by 6
Ott, F., Körner, C., Werner, K., Gericke, M. T., Liebscher, I., Lobsien, D., Radrezza, S., Shevchenko, A., Hofmann, U., Kratzsch, J., et al. (2022) · Cells · doi:10.3390/cells11101680 · Cited by 6
Hazebroek, M. K., & Keipert, S. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.909621 · Cited by 6
Steinhoff, J. S., Wagner, C., Taschler, U., Wulff, S., Kiefer, M. F., Petricek, K. M., Wowro, S. J., Oster, M., Flores, R. E., Yang, N. Y., et al. (2022) · Journal of Lipid Research · doi:10.1016/j.jlr.2022.100268 · Cited by 6
Soares, G. M., Balbo, S. L., Bronczek, G. A., Vettorazzi, J. F., Marmentini, C., Zangerolamo, L., Velloso, L. A., & Carneiro, E. M. (2023) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00218.2023 · Cited by 5
Xu, L., Yu, H., Yin, J., Li, L., Zhou, J., Li, M., Li, Q., Chen, H., Liu, F., Bao, Y., et al. (2017) · Scientific Reports · doi:10.1038/srep43123 · Cited by 6
Rajan, S., Mandikian, D., Baruch, A., Gelzleichter, T. R., Stevens, D. W., Sonoda, J., Cowan, K. J., Boswell, C. A., & Stefanich, E. G. (2017) · mAbs · doi:10.1080/19420862.2017.1373923 · Cited by 6
Bioengineering of FGFs and New Drug Developments
Li, X. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-816142-5.00008-4 · Cited by 7
Gehring, J., Azzout‐Marniche, D., Chaumontet, C., Piedcoq, J., Gaudichon, C., & Even, P. C. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00246.2021 · Cited by 7
Ye, X., Qi, J., Wu, Q., Yu, D., Li, S., Wu, Y., & Li, D. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.04.025 · Cited by 6
Olivares, S., & Henkel, A. S. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.09.006 · Cited by 6
Oral bezafibrate induces daily torpor and FGF21 in mice in a PPAR alpha dependent manner
Chu, L. P., & Swoap, S. J. (2011) · Journal of Thermal Biology · doi:10.1016/j.jtherbio.2011.11.011 · Cited by 6
The role of FGF21 in the metabolic adjustments required for exercise capacity
Abe, L., & Dantzer, R. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123940 · Cited by 5
Exerkines: Benign adaptation for exercise and benefits for non-alcoholic fatty liver disease
Chen, Y., Zhang, Y., Jin, X., Hong, S., & Tian, H. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.150305 · Cited by 5
Self-citationPeixoto, Á. S., Moreno, M. F., Castro, É., Perandini, L. A., Belchior, T., Oliveira, T. E., Vieira, T. S., Gilio, G. R., Tomazelli, C. A., Leonardi, B. F., et al. (2023) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-023-00970-4 · Cited by 6
Salama, A. M., Elmahy, R. A., Ibrahim, H. A., Amer, A. I. M., Eltantawy, A. F., & Elgendy, D. I. (2023) · Parasitology Research · doi:10.1007/s00436-023-08011-1 · Cited by 6
Activin E upregulates uncoupling protein 1 and fibroblast growth factor 21 in brown adipocytes
Sakaki, M., Kamatari, Y. O., Kurisaki, A., Funaba, M., & Hashimoto, O. (2024) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2024.112326 · Cited by 5
Treating metabolic dysfunction‐associated steatohepatitis: The fat‐trimming FGF21 approach
Li, X., Rao, Z., Hu, W., Lu, W., & Luo, Y. (2024) · Obesity Reviews · doi:10.1111/obr.13861 · Cited by 6
Age of Cafeteria Diet Onset Influences Obesity Phenotype in Mice in a Sex-Specific Manner
Bazhan, N., Kazantseva, A., Dubinina, A., Balybina, N. Y., Jakovleva, T., & Makarova, E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212436 · Cited by 4
Misceo, D., Mocciaro, G., D’Amore, S., & Vacca, M. (2024) · Nutrition & Metabolism · doi:10.1186/s12986-024-00871-3 · Cited by 6
Zhen, J., Liu, S., Liu, L., Zheng, X., Zhao, G., Liang, J., Xu, A., Li, C., Ren, L., Wu, J., et al. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2500689 · Cited by 5
Peng, Z., Gao, L., Zhang, L., Yao, R., Li, X., Deng, L. J., Fan, J., Ying, L., & Wang, Y. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146577 · Cited by 5
Kurtak, K. A. (2013) · Rejuvenation Research · doi:10.1089/rej.2013.1485 · Cited by 5
Song, Y., Zhang, Y., Lyu, X., Gu, Y., Zhang, G., Liu, P., Zheng, Y., Guo, Z., Zhang, Y., & Hou, H. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.874796 · Cited by 5
Direct activation of the fibroblast growth factor-21 pathway in overweight and obese cats
Brinker, E. J., Towns, T. J., Watanabe, R., Ma, X., Bashir, A., Cole, R. C., Wang, X., & Graff, E. C. (2023) · Frontiers in Veterinary Science · doi:10.3389/fvets.2023.1072680 · Cited by 5
The secretome as a biomarker and functional agent in heart failure
Nyarko, O. O., & Sucharov, C. C. (2023) · The Journal of Cardiovascular Aging · doi:10.20517/jca.2023.15 · Cited by 5
Hyperphagia of female UCP1-deficient mice blunts anti-obesity effects of FGF21
Hazebroek, M. K., Laterveer, R., Kutschke, M., Marčeta, V. R., Barthem, C. S., & Keipert, S. (2023) · Scientific Reports · doi:10.1038/s41598-023-37264-0 · Cited by 5
Juan, Z., Liu, X., Yue, J., Zhang, S., Li, L., & Wei, H. (2024) · Frontiers in Veterinary Science · doi:10.3389/fvets.2024.1429639 · Cited by 5
Stengel, A., Coşkun, T., Goebel‐Stengel, M., Craft, L. S., Alsina‐Fernandez, J., Wang, L., Rivier, J., & Taché, Y. (2011) · Regulatory Peptides · doi:10.1016/j.regpep.2011.01.006 · Cited by 5
Treatment with FGFR2-IIIc monoclonal antibody suppresses weight gain and adiposity in KKAy mice
Nonogaki, K., Kaji, T., Yamazaki, T., & Murakami, M. (2016) · Nutrition and Diabetes · doi:10.1038/nutd.2016.41 · Cited by 5
Arfuso, F., Giannetto, C., Panzera, M. F., Fazio, F., & Piccione, G. G. (2021) · Animals · doi:10.3390/ani11061836 · Cited by 5
Kuo, Y., Tsai, H.-Y., Kuo, Y., Tzeng, S., Chen, P.-S., Hsu, P., Lin, Y., & Chen, P. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121900 · Cited by 5
Reinehr, T., Roth, C. L., & Woelfle, J. (2016) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2015-0074 · Cited by 5
Ribel-Madsen, A., Ribel‐Madsen, R., Nielsen, K. F., Brix, S., Vaag, A. A., & Brøns, C. (2018) · Scientific Reports · doi:10.1038/s41598-018-21419-5 · Cited by 5
Moreno-Lopez, M., Louvet, I., Delalleau, N., Acosta-Montalvo, A., Thévenet, J., Pasquetti, G., Gmyr, V., Kerr-Conte, J. A., Pattou, F. N., Bonner, C., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16089 · Cited by 4
Huang, Y., Liu, B., Hu, C., & Lu, Y. (2025) · Protein & Cell · doi:10.1093/procel/pwaf027 · Cited by 4
Self-citationQi, D. E. N. G., Huang, J., Wang, C., & Liang, J. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062746 · Cited by 4
Insights into the role of FGF21 in coronary heart disease
Zhang, Q.-Y., & Liu, H. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.136911 · Cited by 4
Du, P., Wang, T., Wang, R., Liu, S., Wang, H., & Yin, H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062672 · Cited by 4
Deletion of GFRAL blunts weight lowering effects of FGF21 in female mice
Buch-Rasmussen, A. S., Andersen, H., Stage, C., Hansen, A. M. K., Paulsen, S. J., Gillum, M. P., Andersen, B., Secher, A., Latta, M. R., Clemmensen, C., et al. (2025) · Journal of Endocrinology · doi:10.1530/joe-25-0017 · Cited by 4
Plasma Levels of Fibroblast Growth Factor 21 and Adverse Kidney Outcomes
Koh, H. B., Kim, H. J., Kim, H. W., Chang, T. I., Park, J. T., Yoo, T., Kang, S., & Han, S. H. (2025) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2024.10.026 · Cited by 4
Małkowska, P., Tomasiak, P., Tkacz, M., Zgutka, K., Tarnowski, M., Maciejewska, A., Buryta, R., Rosiński, Ł., & Sawczuk, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157115 · Cited by 4
Potential role of Akt in the regulation of fibroblast growth factor 21 by berberine
Hirai, T., Wang, W., Murono, N., Iwasa, K., & Inoue, M. (2023) · Journal of Natural Medicines · doi:10.1007/s11418-023-01755-1 · Cited by 4
Bourdon, G., Chevaleyre, C., Estienne, A., Péchoux, C., Bourgeais, J., Hérault, O., Ba, M., Ramé, C., Dupont, J., Ducluzeau, P., et al. (2024) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2024.112350 · Cited by 2
Saponins from Panax japonicus Enhance Lipolysis via Acting on FGF21-β-Klotho/FGFR1 in Obese Mice
Wang, T., Huang, Y., Hu, M., Huang, X., Yu, D., Jia, L., Zhi, W., Mu, Y., Zhou, Z., & Wang, J. (2025) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.5c01012 · Cited by 4
Brain Inflammation and Endoplasmic Reticulum Stress
Çakır, I., & Nillni, E. A. (2018) · Springer eBooks · doi:10.1007/978-3-319-89506-2_4 · Cited by 4
Bibliometric analysis of fibroblast growth factor 21 research over the period 2000 to 2021
She, Q.-Y., Li, L., Liu, M.-H., Tan, R.-Y., Zhong, Y.-W., Bao, J., & Xie, J.-D. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1011008 · Cited by 9
Efficacy of fibroblast growth factor 21 in non‐alcoholic fatty liver disease in guinea pigs
Klæbel, J. H., Lykkesfeldt, J., & Tveden‐Nyborg, P. (2022) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13705 · Cited by 4
Stability and Glucose Regulation of FGF21 After Modified With Arginines*
Kun, H. E., Zhang, Y., Ye, X., Wang, W., Chen, R., Liu, M., Feng, M., Xu, J., & Li, D. (2012) · PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS · doi:10.3724/sp.j.1206.2012.00007 · Cited by 4
Shafaei, A., Khoshnia, M., & Marjani, A. (2015) · Journal of Medical Sciences(Faisalabad) · doi:10.3923/jms.2015.80.86 · Cited by 4
Therapeutic potential of FGF21 in diabetes
Davis, D., Garg, C., & Lahiri, S. (2017) · Journal of Medicinal Plants Studies · Cited by 4
Chen, S.-H., & Chao, P. (2017) · PLoS ONE · doi:10.1371/journal.pone.0187507 · Cited by 4
Norlin, J., Dermit, M., Sidiropoulos, N., Galsgaard, E. D., Hansen, H. H., Feigh, M., Veidal, S. S., Latta, M. R., Henriksson, E., & Andersen, B. (2025) · PLoS ONE · doi:10.1371/journal.pone.0331665 · Cited by 3
The role of β-Klotho in FGF signaling: from molecular insights to therapeutic innovations
Yan, F., Yang, C., Huang, S., Yuan, L., Qiu, Y., Liu, T., Peng, X., & Yang, Y. (2026) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00042.2026 · Cited by 4
Szczepańska, E., Glinicki, P., Zgliczyński, W., Slowinska-Srzednicka, J., Jastrzębska, H., & Gietka‐Czernel, M. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.900034 · Cited by 3
Sakamoto, S., Kakehi, S., Abudurezake, A., Kaga, H., Someya, Y., Tabata, H., Yoshizawa, Y., Naito, H., Tajima, T., Ito, N., et al. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188241280540 · Cited by 3
Genetics of Energy and Macronutrient Intake in Humans
Tanaka, T. (2014) · Current Nutrition Reports · doi:10.1007/s13668-014-0083-5 · Cited by 3
Yavari, R., Bostanabad, S. Z., & Gharibi, A. (2019) · International Journal of Advanced Biological and Biomedical Research · doi:10.33945/sami/ijabbr.2019.2.6 · Cited by 3
Nuclear Receptors in Energy Metabolism
Walth-Hummel, A. A., Herzig, S., & Rohm, M. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-11836-4_4 · Cited by 4
Xie, J., Shao, Y., Liu, J., Cui, M., Xiao, X., Gong, J.-B., Xue, B., Zhang, Q., Hu, X., & Duan, H. (2020) · Scientific Reports · doi:10.1038/s41598-020-77096-w · Cited by 3
Fibroblast Growth Factor 21 is a Regulator of Energy Metabolism in the Liver and Adipose Tissue
Matikainen, N. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-407869-7.00039-8 · Cited by 3
Schibler, U., Asher, G., Saini, C., Morf, J., & Reinke, H. (2009) · Springer eBooks · doi:10.1007/978-3-642-00150-5_34 · Cited by 3
Frayling, T. M., Beaumont, R. N., Jones, S. E., Yaghootkar, H., Tuke, M. A., Ruth, K. S., Casanova, F., West, B., Locke, J. M., Sharp, S. A., et al. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/214700 · Cited by 3
Oral gene delivery platform based on glycol chitosan-PEG-lactoferrin conjugate
Jang, S., Priscilla, L., Lee, C. W., Lee, S. A., Lee, M., & Lee, D. Y. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114463 · Cited by 2
Metadata
- Authors
- Coskun, T., Bina, H. A., Schneider, M. A., Dunbar, J. D., Hu, C. C., Chen, Y., Moller, D. E., & Kharitonenkov, A.
- Affiliations
- Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana 46285
- Eli Lilly (United States) (US)
- Corresponding author
- Kharitonenkov, Alexei
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2008-08-07
- Volume
- 149
- Issue
- 12
- Pages
- 6018-6027
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W2114650931
- Cited by
- 1,031
- References
- 26
- Citations by year
- 2026: 17 · 2025: 34 · 2024: 58 · 2023: 63 · 2022: 57 · 2021: 72 · 2020: 67 · 2019: 76 · 2018: 72 · 2017: 64 · 2016: 78 · 2015: 85 · 2014: 71 · 2013: 62 · 2012: 61
- FWCI
- 12.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- FGF21, obesity, diet-induced obesity, ob/ob mice, energy expenditure, fat oxidation, de novo lipogenesis, hepatic steatosis, insulin resistance, leptin resistance, glycemia, lipid excretion, adipose tissue, metabolic therapy
- MeSH terms
- Animals, Body Weight, Energy Intake, Dietary Fats, Energy Metabolism, Fibroblast Growth Factors, Insulin, Insulin Resistance, Male, Mice, Inbred C57BL, Motor Activity, Obesity, Leptin, Adiposity, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
